The role of CD93 in shaping the immune microenvironment and predicting immunotherapy response in advanced non-small cell lung cancer
In recent years, immunotherapy has substantially improved the clinical outcomes and survival benefits of patients with advanced non-small cell lung cancer (NSCLC). However, more than half of patients fail to achieve durable or clinically meaningful therapeutic responses. Therefore, identifying patients who are most l...